Anti-Cancer Drug Reverses Alzheimer's Disease In Mice
An anti-cancer drug may reverse memory problems in an Alzheimer's Disease mouse model, according to new research carried out at the University of Pittsburgh Graduate School of Public Health. The study, published in the journal Science, examined previously published outcomes on the drug bexarotene - which is approved by the U.S. Food and Drug Administration for use in cutaneous T cell lymphoma... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 25, 2013 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
Copy Number Analysis in EBV-Positive Nodal Peripheral T Cell Lymphoma, Unspecified
Copy number alteration was investigated in three cases of EBV + nodal peripheral T cell lymphoma of cytotoxic phenotype using Agilent array comparative genomic hybridization platform. While no recurrent abnormality among three cases was identified, genomic abnormalities involving 9p23.3, 16p13.3, and 7q34 were overlapped with changes reported in other type of NK or T cell lymphomas previously. Chromosomal region 9p23.3 contains CDKN2A and CDKN2B which are frequently mutated or deleted in various types of cancer and may be a target to find genes associated with the pathogenesis of EBV-positive nodal peripheral T cell lympho...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news
Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of Adcetris (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL)
ˆ’ Phase III Clinical Trial Designed to
Examine the Use of ADCETRIS as Part of a Front-line Treatment
Regimen for Newly Diagnosed MTCL Patients, Including Systemic
Anaplastic Large Cell Lymphoma and Other Types of Peripheral... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 24, 2013 Category: Pharmaceuticals Source Type: news
T-Cell Lymphomas: Moving Forward, Improving OutcomesT-Cell Lymphomas: Moving Forward, Improving Outcomes
Dr. Julie Vose discusses some of the challenges in diagnosis and management of T-cell lymphomas and looks at how new, targeted therapies offer hope for better outcomes. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology Expert Interview Source Type: news
Flow Cytometry for Non-Hodgkin and Classical Hodgkin Lymphoma
Multiparametric flow cytometry is a powerful diagnostic tool that permits rapid assessment of cellular antigen expression to quickly provide immunophenotypic information suitable for disease classification. This chapter describes a general approach for the identification of abnormal lymphoid populations by flow cytometry, including B, T, and Hodgkin lymphoma cells suitable for the clinical and research environment. Knowledge of the common patterns of antigen expression of normal lymphoid cells is critical to permit identification of abnormal populations at disease presentation and for minimal residual disease assessment. W...
Source: Springer protocols feed by Cancer Research - January 11, 2013 Category: Cancer & Oncology Source Type: news
TG Therapeutics commences TGR-1202 Phase I trial
TG Therapeutics has begun first-in-human, Phase I trial of TGR-1202 in patients suffering from hematologic malignancies such as relapsed or refractory Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Peripheral T-Cell Lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - January 9, 2013 Category: Pharmaceuticals Source Type: news
Classification of Mycosis Fungoides and Sezary SyndromeClassification of Mycosis Fungoides and Sezary Syndrome
This article focuses on the evaluation and classification of mycosis fungoides and Sezary syndrome, two of the most common forms of cutaneous t-cell lymphoma. What treatment options are available? Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options
Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra™, GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax®, Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL).
November 23, 2009
FORT WASHINGTON, PA - Two recent FDA approvals have prompted the National Comprehensive Cance... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 23, 2009 Category: Cancer & Oncology Source Type: news
NCCN Receives Research Grant to Evaluate Pralatrexate in Solid Tumors and Hematologic Malignancies
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
November 10, 2009
FORT WASHINGTON, PA — The National Comprehensive Cancer Networ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 10, 2009 Category: Cancer & Oncology Source Type: news
NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate
NCCN has added pralatrexate (Folotyn™, Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma. The FDA approved pralatrexate for the treatment of peripheral T-cell lymphoma on September 25, 2009.
October 15, 2009
FORT WASHINGTON, PA - Upon the recent FDA approval of pralatrexate (Folotyn™, Allos Therapeutics, Inc.) for the treatment of relapsed or refractory peripheral ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - October 15, 2009 Category: Cancer & Oncology Source Type: news
Combination Cancer Therapy is Focus of $1M Merck Research Grant Received by NCCN
NCCN has been awarded a $1M research grant from Merck & Co, Inc., that will support research of the anti-cancer agent vorinostat (Zolinza®). Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the efficacy of vorinostat in combination with chemotherapy and/or radiation therapy in selected locally advanced non-metastatic cancers including non-small cell lung cancer, head and neck cancer, panc... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - December 1, 2008 Category: Cancer & Oncology Source Type: news
NCCN Updates Non-Hodgkin’s Lymphoma Guidelines
JENKINTOWN, Pa., June 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Non-Hodgkin’s Lymphoma (NHL) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are updated continuously by panels of world-renowned experts and are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings.
The NHL Panel added new guidelines for peripheral T-Cell lymphomas, a group of ag... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - June 19, 2007 Category: Cancer & Oncology Source Type: news
NCCN Updates Non-Hodgkin ’s Lymphoma Guidelines
JENKINTOWN, Pa., June 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Non-Hodgkin’s Lymphoma (NHL) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are updated continuously by panels of world-renowned experts and are widely recognized and applied as the standard of care i n oncology in the United States in both the community and the academic practice settings.
The NHL Panel added new guidelines for peripheral T-Cell lymphomas, a group of ag... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - June 19, 2007 Category: Cancer & Oncology Source Type: news
